Allergan (NYSE: AGN) today confirmed that it’s in the running to acquire Shire (NSDQ:SHPGY), which rejected a $63 billion offer from Takeda Pharmaceutical (TYO:4502).
Dublin-based Allergan, which is in the process of slashing 1,400 jobs from its payroll and exploring “strategic actions,” said there’s no guarantee it will make an offer for Shire.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan, Takeda spar for Spire appeared first on MassDevice.
from MassDevice https://ift.tt/2J50csL
Cap comentari:
Publica un comentari a l'entrada